Skin complications during iron chelation therapy for beta-thalassemia: overview and treatment approach

Int J Hematol. 2024 Sep;120(3):271-277. doi: 10.1007/s12185-024-03825-w. Epub 2024 Aug 1.

Abstract

Thalassemia is an inherited genetic disorder of hemoglobin that affects a large population worldwide, and it is estimated that between 50,000 and 60,000 infants with thalassemia are born each year. The most common treatment for thalassemia is blood transfusion, which leads to iron overload. This in itself is a serious clinical condition, and is commonly managed with iron chelation therapy. However, iron chelators can cause various skin complications, including hyperpigmentation, skin rash, itching, and photosensitivity. These skin side effects can impact patients' quality of life. Therefore, this article provides a comprehensive overview of skin complications caused by iron chelators, along with a proposed comprehensive approach to their management in patients with beta-thalassemia. Key strategies include patient education, regular skin assessment, sun protection measures, symptomatic relief with topical corticosteroids and antihistamines, and consideration of treatment modification if severe complications occur. Collaboration between hematologists and dermatologists, along with psychological support and regular follow-up, is an essential component of this multidisciplinary approach. By implementing these strategies, healthcare providers can optimize skin care for patients with beta-thalassemia treated with iron chelators and improve their quality of life.

Keywords: Beta-thalassemia; Iron chelators; Skin complications.

Publication types

  • Review

MeSH terms

  • Chelation Therapy*
  • Humans
  • Iron Chelating Agents* / adverse effects
  • Iron Chelating Agents* / therapeutic use
  • Iron Overload / drug therapy
  • Iron Overload / etiology
  • Quality of Life*
  • Skin Diseases / chemically induced
  • Skin Diseases / etiology
  • Skin Diseases / therapy
  • beta-Thalassemia* / complications
  • beta-Thalassemia* / drug therapy
  • beta-Thalassemia* / therapy

Substances

  • Iron Chelating Agents